Publications

5543 Results

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT# 04511013)

Authors
Z Eroglu;J Moon;H Tawbi;Y Najjar;R Kotecha;V Spektor;M Wu;E Sharon;J Wolchok;S Patel
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9603); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), TIP poster session
Year
2023
Research Committee(s)
Melanoma
Study Number(s)
S2000

Rural cancer care delivery during the COVID-19 pandemic for patients with early-stage cancer

Authors
I Okado;M Liu;C Elhajj;L Wilkens;R Holcombe
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr e18566); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), publication only
Year
2023
Research Committee(s)
Cancer Care Delivery

The Association of Sociodemographic Variables with Smoking Prevalence in Patients Enrolled on Clinical Trials

Authors
C Preasant;R Vaidya;C Till;K Ashing;G Warren;D Hershman;V Sun;S Subbiah;R Salgia;E Massarelli;J Mortimer;M Fakih;S Pal;A Amini;L Erhunmwsee;T Phillips;S Rosen;J Unger
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr e13595); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), publication only
Year
2023
Research Committee(s)
Cancer Care Delivery

Association of Baseline Measures of Socioeconomic Deprivation and Healthcare Utilization in Patients Enrolled in SWOG Cancer Clinical Trials

Authors
D Hershman;R Vaidya;C Till;W Barlow;M LeBlanc;S Ramsey;J Unger
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 6527); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Cancer Care Delivery

SWOG S1823/CCTG GCC1 - Translational Observational Investigational Study of the Liquid Biomarker microRNA 371a-3p in Newly Diagnosed Germ Cell Tumours - Real-World Trial Design, Rapid Accrual, and Robust Secondary Use of Data Opportunities

Authors
A Morin Coulombe;G Ozgun;R Johnson;M Lewis;N Adra;S Eggener;B Roth;C Ryan;C Porter;F Millard;T Jang;R Hamilton;L Einhorn;C Kollmannsberger;K Arnold;C Blanke;S Daneshmand;A Harzstark;C Nichols;L Nappi
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS5103); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), TIP poster session
Year
2023
Research Committee(s)
Genitourinary, Prevention, Screening, and Surveillance, Prevention, Screening, and and Surveillance
Study Number(s)
S1823

Impact of COVID-19 Pandemic Mitigation Strategies on Industry and NCI Cancer Treatment Trials

Authors
J Unger;C Schenkel;H Stires;L Levit;M Stewart;B Mckelvey;B Canin;E Dressler;K Flaherty;P Fredette;L Jones;M McCann;T Miller;A Onitilo;F Palmieri;T Patel;R Paul;G Smith;S Bruinooge;A Alva
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 1565); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Cancer Care Delivery

Adjuvant everolimus in patients (Pts) with localized non-clear cell renal cell carcinoma (RCC): Subgroup analysis from the Everest trial (SWOG S0931)

Authors
S Gulati;C Tangen;C Ryan;U Vaishampayan;B Shuch;P Barata;D Pruthi;C Bergerot;A Tripathi;IM Thompson;P Lara;S Pal
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 4546); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S0931

Adjusted indirect treatment comparison of progression-free survival (PFS) associated with DRd and VRd based on MAIA and SWOG S0777 individual patient-level data

Authors
B Durie;S Kumar;E Ammann;A Fu;S Kaila;A Lam;S Usmani;T Facon
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 8037); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
Year
2023
Research Committee(s)
Myeloma
Study Number(s)
S0777

Diversity, equity, and inclusion (DEI) champions: Lessons learned and implications for future programming to support cancer clinical trials

Authors
C Figueroa-Moseley;L Gansauer;J McDermott;M Espinoza Gutarra;G Nagaraj;P Robinson;R Bangs;A Caban-Holt
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr e18529); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), publication only
Year
2023
Research Committee(s)
Cancer Care Delivery

Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

Authors
S Halabi;A Roy;S Guo;L Rydzewska;P Godolphin;M Hussain;C Tangen;IM Thompson;W Xie;M Carducci;M Smith;M Morris;G Gravis;D Dearnlavey;P Verhagen;T Goto;J Tierney;N James;M Buyse;C Sweeney
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 5070); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-9346